Maladie de Vaquez Prise en charge 2018, Dr. Yan Beauverd, 26.06.18

Menu

1. MALADIE DE VAQUEZ PRISE EN CHARGE EN 2018
2. Myeloproliferative neoplasm 2016 WHO classification
3. EPIDEMIOLOGY
4. Driver mutations
5. PV evolution
6. pv related symptoms
7. SYMPTOMS
8. MPN10 SCORING SYSTEM
9. Pv related complications
10. Splanchnic vein thrombosis
11. Risk factors for thrombosis
12. survival
13. survival
14. Impact on employment status and work productivity
15. DIAGNOSIS
16. Algorithm for the diagnosis of erythrocytosis
17. Goals of treatment
18. Target haematocrit (cyto-pv study)
19. low-dose aspirine (eclap study)
20. HYDROXYUREA (1)
21. HYDROXYUREA (2)
22. Interferon (1)
23. Interferon (2)
24. RUXOLITINIB (jak INHIBITOR)
25. RUXOLITINIB (jak INHIBITOR)
26. Ruxolitinib vs BAT
27. SUMMARY
28. TREATMENT RECOMMENDATION (ELN 2018)
29. TAKE HOME MESSAGE
30. Slide 30
31. Slide 31
32. SURVIVAL
33. Impact on employment status and work productivity
34. MASQUED PV
35. RUXOLITINIB (jak INHIBITOR)
36. RUXOLITINIB (jak INHIBITOR)

FINISH

SUBMIT

NEXT

PREV